Evaluation of Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.

Phase 3

Completed

• Conditions: Seizure Disorder, Partial

• Registration Number: NCT00150293
• Lead Sponsor: Pfizer

Brief Summary

To determine long-term safety and efficacy of pregabalin in patients with partial seizures.

Detailed Description

Not available

Study Timeline

• Study Start: 2002-03
• Study First Submitted: 2005-09-06
• Study First Submitted QC: 2005-09-06
• Study First Posted: 2005-09-08
• Study Completion: 2005-11
• Status Verified: 2015-03
• Last Update Submitted: 2015-03-04
• Last Update Posted: 2015-03-05

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 337

Inclusion Criteria

• Must have met the inclusion criteria for preceding double-blind study
• Have received double-blind study medication and wish to receive open-label pregabalin.

Exclusion Criteria

• Cannot be pregnant or considering becoming pregnant during the course of the study.
• Cannot be receiving any concomitant medication that could alter the effectiveness of the pregabalin response or affect seizure frequency.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Safety Efficacy

Trial Locations

Locations (1)

Pfizer Investigational Site